Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Arctic Bioscience AS ( (DE:9TD) ) is now available.
Arctic Bioscience has finalized an increase in share capital from NOK 2,685,934 to NOK 2,695,625.60 through the issuance of new shares following debt conversion rights. This development reflects the company’s strategic steps to strengthen its financial position, potentially bolstering its operations and industry standing as it continues to develop innovative biotech solutions for psoriasis treatment and marine-based nutraceuticals.
More about Arctic Bioscience AS
Arctic Bioscience is a biotech firm specializing in pharmaceutical and nutraceutical products derived from bioactive marine compounds. The company is developing HRO350, an innovative oral drug targeting mild-to-moderate psoriasis, addressing unmet needs for effective and safe medicines, while also offering nutraceuticals globally under the ROMEGA® brand.
Average Trading Volume: 28,851
Current Market Cap: NOK98.31M
For an in-depth examination of 9TD stock, go to TipRanks’ Overview page.